NewsRx

Search our medical news database

Drug Law Weekly

Susan Hasty, Publisher

Table of Contents . . . February 28th, 2006

Non-Subscriber - Summaries Only

Related Areas: Other Issues in Drug Law Weekly | Other Publications

Amarin Corp. plc - Neuroscience drug maker reports loss of $0.10 per share

AtheroGenics, Inc. - Commercialization deal signed for atherosclerosis treatment

Bayer Group - Abbott Laboratories grants rights for new cancer and transplantation drug tests

Collaborations - Louisiana court partners with Southern University to evaluate substance abuse protocols

CytRx Corp. - Article indicates drug target RIP140 controls insulin sensitivity and glucose tolerance

Gastroesophageal Reflux Disease - Medicare increases reimbursement rate for Plicator procedure

Genetic Technologies, Ltd. - DNA-focused company expands licensing program, hires PatentBridge

GeoPharma, Inc. - Drugmaker announces dismissal of amended class action complaint relating to Mucotrol

Healthcare Costs - Administration says Medicare drug coverage will drop overall costs substantially

Healthcare Costs - Pediatricians vote to cut children's healthcare

Information Technology - Partners In Care participates in federally funded test of electronic prescribing program

J. Bolen Group, LLC - Dominion Diagnostics and "The Legal Side of Pain" announce a joint venture

Medicare - Pennsylvania governor seeks to expand comprehensive drug package for seniors

Medicare - Pharmacy services firm questions perceived savings of Medicare drug plan

NxStage Medical, Inc. - First patient enrolled in FREEDOM daily home hemodialysis study

ALZA Corp. - European Commission approves IONSYS

Advancis Pharmaceutical Corp. - Infectious disease-focused pharmaceutical firm appoints chairman of the board

Aga Khan University, Karachi - Reports advance knowledge in urology research

Alfacell Corp. - New thoracic cancer advisory board formed

All India Institute of Medical Science, New Delhi - Chemotherapy alone used to treat Hodgkin disease in Indian children

Alnylam Pharmaceuticals, Inc. - Public offering of common stock priced by RNAi therapeutics company

Apoxis SA - U.S. FDA grants orphan medicinal product designation for rare disease protein therapeutic

Archemix Corp. - Aptamer-based therapeutic developer moves to new headquarters

Arena Pharmaceuticals, Inc. - Phase I trial of Type 2 diabetes drug initiated

Ariad Pharmaceuticals, Inc. - Cancer drug developer reports loss of $0.99 per share, provides clinical pipeline update

Arpida, Ltd. - Good bioavailability reported from phase I trial of iclaprim

Athens University Medical School - Gastrinomas associated with MEN-1 syndrome

AtheroGenics, Inc. - Research and development collaboration with Astellas Pharma extended

Axonyx, Inc. - Data on Phenserine and Posiphen for Alzheimer disease to be presented in Geneva

Baker Heart Research Institute, Melbourne - Hypoalphalipoproteinemia in HIV/AIDS likely to be secondary to HIV infection itself

Behavior Disorders - Comprehensive Behavioral Care expands services to Maryland and Washington, DC

Behavioral Therapy - Brief relationship therapy was more cost effective than other therapies for alcohol addiction

Belfast City Hospital - Prolyl hydroxylase domain protein 2 is essential for hypoxia-inducible factor regulation

BioMS Medical Corp - Icon retained for phase II/III trial for MBP8298 to treat multiple sclerosis

Bionovo, Inc. - Phase II trial of MF101 launched for treatment of menopausal symptoms

Breast Cancer - Surgery best for controlling breast cancer in older women

Brigham & Women's Hospital, Boston -  Pseudomonas vaccine elicits passive protection against corneal infection

British Columbia Center for Excellence in HIV/AIDS - Methadone maintenance therapy reduces heroin use and HIV risk behavior

Business & Finance - Drug development company subsidiary CDE certified for new market tax credit program

Business Update - Acadia Healthcare announces new operation

CV Therapeutics, Inc. - U.S. FDA approves Ranexa

Calando Pharmaceuticals, Inc. - Partnership formed to develop RNAi therapeutics for childhood cancer

California Department of Health Services - Heparin flush cause of Ralstonia pickettii bacteremia outbreak in neonatal ICU

Cardiff University - Nebivolol is novel beta-blocker with endothelium-derived NO enhancement benefit

Catholic University of Chile - Diurnal noninvasive ventilation beneficial in hypercapnic COPD

Cephalon, Inc. - Regulatory update provided on status of NUVIGIL

Charite Universitatsmedizin, Berlin - Laparoscopic staging enhances treatment planning for women with advanced cervical cancer

Chiba Cancer Center Research Institute - Adenovirus vector is more infective for esophageal and oral carcinoma cells

Chiba University - Tumor cell-stromal fibroblast interaction revealed in model of human small-cell lung cancer

Children's Medical Center of Israel - Antidepressant use in pregnancy appears associated with neonatal withdrawal symptoms

Children's Memorial Hospital, Chicago - HSCT feasible in infants with acute lymphoblastic leukemia

Chonbuk National University, Chonju - Flavonoids inhibited cell growth and induced apoptosis in osteosarcoma cells

Chronic Obstructive Pulmonary Disease - Emotional burden of COPD may make patients reluctant to seek treatment, survey shows

Cipher Pharmaceuticals, Inc. - Drugmaker provides CIP-Tramadol Extended Release update

Cleveland Clinic - Researchers studied natural history of valvular regurgitation in anorexigen-treated subjects

Cobalis Corp. - Dr. Gerald Yakatan joins allergy company's board of directors

Coley Pharmaceutical Canada - HBV CpG-optimized protein and DNA vaccines perform poorly in chimpanzees

CombinatoRx, Inc. - Collaboration to develop ophthalmic therapeutics built from synergistic drug combinations

ConjuChem, Inc. - PC-DAC:Exendin-4 to advance into human clinical testing for type 2 diabetes

Creighton University Cardiac Center, Omaha - Routine screening for antiplatelet drug resistance should not yet be standard practice

Cue Biotech, Inc. - Lundbeck, collaborator to discover allosteric modulators of G-protein coupled receptors

Dana Farber Cancer Institute, Boston - Alternative medicine use is not uncommon following genetic testing results for BRCA1/2

Decision Resources, Inc. - Generics erosion will lead to slow market growth for chronic heart failure treatment

Discovery Laboratories, Inc. - U.S. FDA grants Surfaxin fast track designation for prevention and treatment of BPD

Florida State University - Molecular mechanism discovered that inhibits HCV replication in vitro

GenExel-Sein, Inc. - U.S. FDA clears combined blood glucose, blood pressure monitor for home use

GlaxoSmithKline - U.S. FDA approves new formulation of Imitrex injection

Global AIDS Alliance - Call issued for Anglo-French alliance to combat AIDS epidemic

Hollis-Eden Pharmaceuticals, Inc. - Pharmaceutical firm responds to call for acute radiation syndrome therapy for U.S. forces

Insert Therapeutics, Inc. - Investigational New Drug Application filed to test safety of anticancer compound IT-101

Mercer University, Atlanta - Studies add new findings to diabetes therapy body of knowledge

Mylan Laboratories Inc. - Pharma company announces final U.S. FDA approval for alprazolam extended-release tablets

New River Pharmaceuticals Inc. - U.S. FDA accepts new drug application for NRP104 as treatment for ADHD

OptiMedica Corporation - Ocular disease technology company introduces new photocoagulator

Schering-Plough - U.S. FDA grants fast track designation to investigational oral HCV protease inhibitor

U.S. Centers for Disease Control & Prevention - Dengue proteins offer limited protection to interferon-deficient mice

U.S. Food & Drug Administration - Agency approves new treatment for gastrointestinal and kidney cancer

U.S. Food & Drug Administration - Scientists characterize hot-melt extruded poly(ethylene oxide) films

University of California, San Francisco - Vaginal swabs are best when screening for chlamydia and gonorrhea

University of Hong Kong - Avian influenza virus infections in humans are focus of review

University of Oklahoma - Pediatric immune response zones are established for Cylex ImmuKnow assay

Return to Top of Page

NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook